The recent identification of USP28 loss in a significant number of p53-proficient tumors that exhibit p53-deficient transcriptional signatures suggests that the MSP may be selected against in a subset of cancers (Fito-Lopez et al., 2023). The gene discussed is USP28; the disease is cancer.